LIN Shanshan 1,2 , WANG Xianliang 1 , YANG Ying 1,3 , LIU Chunxiang 4 , GE Zhao 1,2 , ZHANG Junhua 4 , MAO Jingyuan 1
  • 1. First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin 300381, P.R.China;
  • 2. Graduate School of Tianjin University of Traditional Chinese Medicine, Tianjin 301617, P.R.China;
  • 3. Tianjin Nankai District Traditional Chinese Medicine Hospital, Tianjin 300199, P.R.China;
  • 4. Evidence-Based Medicine Center, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, P.R.China;
MAO Jingyuan, Email: jymao@126.com
Xinmailong injection; Heart failure; Ejection fraction; Meta-analysis; Systematic review; Randomized controlled trial
10.7507/1672-2531.202008145
Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables References Cited by

Objective To systematically review the efficacy and safety of Xinmailong injection in the treatment of different types of heart failure with ejection fraction.Methods CNKI, WanFang Data, VIP, CBM, PubMed, EMbase and The Cochrane Library databases were electronically searched to collect randomized controlled trials (RCTs) of Xinmailong injection in the treatment of different types of heart failure with ejection fraction from inception to August 5th, 2020. Two reviewers independently screened literature, extracted data and assessed risk of bias of included studies. Meta-analysis was then performed using RevMan 5.3 software.Results A total of 25 RCTs involving 2 467 patients were included. The results of meta-analysis showed that Xinmailong injection combined with conventional therapy was superior to conventional therapy alone on NYHA classification efficiency (HFrEF: RR=1.32, 95%CI 1.04 to 1.69, P=0.02), comprehensive clinical efficacy (HFrEF: RR=1.24, 95%CI 1.15 to 1.34, P<0.000 01; HFpEF: RR=1.22, 95%CI 1.15 to 1.30, P<0.000 01), score of life quality (HFrEF: MD=−7.08, 95%CI −9.34 to −4.82, P<0.000 01), left ventricular ejection fraction (HFrEF: MD=4.99, 95%CI 3.18 to 6.80, P<0.000 01; HFpEF: MD=5.10, 95% CI 0.62 to 9.58, P=0.03), the level of B-type natriuretic peptide (HFrEF: SMD=−0.96, 95%CI −1.36 to −0.56, P<0.000 01; HFpEF: SMD=−1.83, 95%CI−2.35 to −1.31, P<0.000 01), the level of N-terminal pro-B natriuretic peptide (HFrEF: SMD=−2.98, 95%CI −4.45 to −1.51, P<0.000 1), and 6-minute walking distance (HFrEF: MD=52.56, 95%CI 34.22 to 70.90, P<0.000 01). There was no significant difference in drug-related adverse reactions between two groups.Conclusions Current evidence shows that Xinmailong injection combined with conventional therapy have good efficacy and safety in the treatment of heart failure with different ejection fractions. Due to limited quality and quantity of the included studies, more high quality studies are required to verify above conclusions.

Citation： LIN Shanshan, WANG Xianliang, YANG Ying, LIU Chunxiang, GE Zhao, ZHANG Junhua, MAO Jingyuan. Xinmailong injection in the treatment of heart failure with different types of ejection fraction: a systematic review. Chinese Journal of Evidence-Based Medicine, 2021, 21(4): 423-430. doi: 10.7507/1672-2531.202008145 Copy

  • Previous Article

    Efficacy and safety of non-pharmacological interventions for sleep disturbance in dementia: a systematic review

  • Next Article

    Efficacy of acupuncture for PCOS infertility: a systematic review